Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV

Neurology

Volumn 74, Issue 19, 2010, Pages 1538-1542

  Cherry, C L ^a,b,c   Affandi, J S ^d   Brew, B J ^e,f   Creighton, J ^g   Djauzi, S ⁱ   Hooker, D J ^a   Imran, D ⁱ   Kamarulzaman, A ^j   Kamerman, P ^k   McArthur, J C ^g,l   Moore, R D ^h,l   Price, P ^d   Smyth, K ^m   Tan, I L ^e   Vanar, S ^j   Wadley, A ^k   Wesselingh, S L ^b,c   Yunihastuti, E ⁱ  

^a BURNET INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g Neurology Unit Calvary Health Care Bethlehem   (Australia)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^j UNIVERSITY OF MALAYA   (Malaysia)

^k UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m The Australian National University   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; STAVUDINE; VIRUS RNA;

ADULT; AGED; ARTICLE; ASIAN; AUSTRALIA; CAUCASIAN; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SENSORY NEUROPATHY; SEROPREVALENCE;

EID: 77952173802     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dd436d     Document Type: Article

References (33)

1. Keswani S, Pardo C, Cherry C, Hoke A, McArthur J. HIV-associated sensory neuropathies. AIDS 2002;16:2105-2117.
2. Cherry C, McArthur J, Hoy J, Wesselingh S. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003;26:195-207.
3. Brew BJ. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve 2003;28:542-552.
4. Cherry C, Skolasky R, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006;66:867-873.
5. Nemni R, Sanvito L, Quattrini A, Santuccio G, Camer-lingo M, Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinemia. J Neu-rol Neurosurg Psychiatry 2003;74:1267-1271.
6. Santoro L, Manganelli F, Briani C, et al. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. J Neurol Neurosurg Psychiatry 2006;77:626-629.
7. Ammendola A, Sampaolo S, Ambrosone L, et al. Peripheral neuropathy in hepatitis-related mixed cryoglobuline-mia: Electrophysiologic follow-up study. Muscle Nerve 2005;31:382-385.
8. Clifford D, Yang Y, Evans S. Neurologic consequences of hepatitis C and human immunodeficiency virus coinfec-tion. J Neurovirol 2005;11(suppl 3):67-71.
9. Estanislao L, Morgello S, Simpson D. Peripheral neuropathies associated with HIV and hepatitis C co-infection: a review. AIDS 2005;19(suppl 3):S135-S139.
10. Cornblath D, Hoke A. Recent advances in HIV neuropathy. Curr Opin Neurol 2006;19:446-450.
11. Cherry C, Affandi J, Imran D, et al. Age and height predict neuropathy risk in HIV patients prescribed stavudine. Neurology 2009;73:315-320.
12. Affandi J, Price P, Imran D, Yuhaningsih E, Djauzi S, Cherry C. Can we predict neuropathy risk before stavu-dine prescription in a resource limited setting? AIDS Res Hum Retroviruses 2008;24:1281-1284.
13. Wadley A, Cherry C, Price P, et al. HIV-associated sensory neuropathy: a comparison of rates and risk factors in Australia and South Africa. Cape Town, South Africa: International AIDS Society Conference; 2009.
14. Smyth K, Affandi J, McArthur J, et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 2007;8:367-373.
15. Cherry C, Wesselingh S, Lal L, McArthur J. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005;65:1778-1781.
16. Authier F, Bassez G, Payan C, et al. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 2003;60:808-812.
17. De Martino L, Sampaolo S, Tucci C, et al. Viral RNA in nerve tissues of patients with hepatitis C infection and peripheral neuropathy. Muscle Nerve 2003;27:102-104.
18. Cherry C, Affandi J, Rosenow A, McArthur J, Wesselingh S, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Res Hum Retroviruses 2008;24:117-123.
19. Hulgan T, Haas D, Haines J, et al. Mitochondrial haplo-groups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005;19:1341-1349. (Pubitemid 41800669)
20. Kallianpur A, Hulgan T, Canter J, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006;20:1503-1513.
21. Woolley I, Faragher M, Ugoni A, Spelman D. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol Infect Epidemiol 1997;1997:33-37.
22. George S, Gebhardt J, Klinzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002;31: 154-162.
23. Clifford D, Smurzynski M, Park L, et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009;73:309-314.
24. Abdool Karim S, Tait D. Hepatitis C virus infection in urban and rural Natal/KwaZulu. S Afr Med J 1993;83: 191-193.
25. Ellis L, Brown D, Conradie J, et al. Prevalence of hepatitis C in South Africa: detection of anti-HCV in recent and stored serum. J Med Virol 1990;32:249-251.
26. Tucker T, Voigt M, Bird A, et al. Hepatitis C virus infection rate in volunteer blood donors from the Western Cape: comparison of screening tests and PCR. S Afr Med J 1997;87:603-605.
27. Vardas E, Sitas F, Seidel K, Casteling A, Sim J. Prevalence of hepatitis C virus antibodies and genotypes in asymptomatic, first-time blood donors in Namibia. Bull World Health Organ 1999;77:965-972.
28. Amin J, Kaye M, Skidmore S, Pillay D, Cooper D, Dore G. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004;5:174-179.
29. Ocama P, Katwere M, Piloya T, et al. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci 2008;8: 8-12.
30. Hennig H, Schlenke P, Kirchner H, Bauer I, Schulte-Kellinghaus B, Bludau H. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods 2000;84:181-199.
31. Smuts H, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995;33:1679-1681.
32. Verbeeck J, Peigue-Lafeuille H, Ross R, et al. HCV genotype 5: epidemiology and spread of an uncommon genotype. J Clin Virol 2008;41:170-171.
33. Cribier B, Rey D, Schmitt C, Lang J, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-1136.